Cellular Repair & Recovery
BPC-157 / KPV
Wolverine Oral
BPC-157 and KPV oral capsule blend
Research context
This preparation combines BPC-157, studied in angiogenic and migration signalling, with KPV, studied in NF-κB pathway modulation, in encapsulated oral format. Each component is characterised independently in the published literature.
Common assays: Component identity by LC-MS · Purity per component · Capsule content uniformity
Specification
| Designation | Wolverine Oral |
|---|---|
| Full name | BPC-157 and KPV oral capsule blend |
| Components | BPC-157 · KPV |
| Formats | Capsules — 30 count |
| Solubility | Encapsulated format |
| Storage | Sealed, 2–8 °C, protected from light and moisture |
Common questions
How is content uniformity verified for capsule products?
By assaying individual capsules across a batch and reporting the distribution, rather than testing a pooled sample. This is what distinguishes a capsule certificate from a bulk powder certificate.
Same pathway
Related compounds
BPC-157
Body Protection Compound-157
A synthetic pentadecapeptide derived from a gastric juice sequence, studied in migration and angiogenesis models.
TB-500
Thymosin beta-4 fragment
A synthetic fragment corresponding to the actin-binding domain of thymosin beta-4.
BPC-157 / TB-500
Peptide blend
A prepared blend of the two most extensively studied compounds in the repair signalling literature.